Samrat Pharmachem Share Price Today | Stock Price & Samrat Pharmachem Share Screener
As of October 5, 2026, the live Samrat Pharmachem share price (BSE: SAMRATPH) is ₹240.40, up 3.24% from the previous close, with shares trading between ₹231.10 and ₹244.00 in today's trading session, and a 52-week range of ₹194.95–₹296.70. Check Samrat Pharmachem yearly highs lows for the annual price range and momentum. Use the Samrat Pharmachem stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Samrat Pharmachem opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹295 and net income of ₹-2, an operating margin of -1.0% and a profit margin of -0.7%.
Samrat Pharmachem Share Price Chart
Track the current stock price of Samrat Pharmachem with an interactive chart. Analyse SAMRATPH share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Samrat Pharmachem stock quote in one place.
The quote of ₹240.40 sits between the 52-week low of ₹194.95 and the 52-week high of ₹296.70, and the latest session moved 3.24% from the previous close.
Samrat Pharmachem Company Profile - Fundamental Screener
Screen Samrat Pharmachem company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SAMRATPH shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE103E01016.
Company Details
Classification
Identifiers and Leadership
Samrat Pharmachem Balance Sheet Screener
Screen SAMRATPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹124, up from ₹122 in 2025.
Latest statistics put total assets at ₹124 and shareholder funds at ₹68, with a leverage ratio of 0.15.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 124 | 122 | 122 | 117 | 85 | 57 | 58 | 40 | 41 | 36 |
| Current Assets | 104 | 103 | 103 | 99 | 71 | 47 | 50 | 33 | 33 | 28 |
| Fixed Assets | 12 | 11 | 11 | 11 | 10 | 9 | 7 | 7 | 7 | 7 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 68 | 72 | 65 | 63 | 47 | 30 | 24 | 20 | 19 | 15 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 65 | 69 | 62 | 60 | 44 | 27 | 21 | 17 | 15 | 12 |
Samrat Pharmachem Income Statement Screener - Profit & Revenue Analysis
Screen Samrat Pharmachem income statement and profit fundamentals. Analyze SAMRATPH quarterly results. Samrat Pharmachem reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹295 and net profit was ₹-2, equal to earnings per unit of ₹-7.10, at an operating margin of -1%.
In that period expenses were ₹295, interest cost ₹1 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹291 and net profit of ₹-3.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 295 | 291 | 287 | 283 | 311 | 222 | 180 | 138 | 112 | 93 | 71 | 62 | 48 |
| Expenses | 295 | 292 | 276 | 279 | 287 | 198 | 170 | 131 | 108 | 87 | 67 | 61 | 46 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 0 | -1 | 11 | 4 | 24 | 25 | 9 | 7 | 4 | 6 | 4 | 1 | 2 |
| Operating Profit % | -1.00% | -1.00% | 4.00% | 1.00% | 8.00% | 11.00% | 5.00% | 5.00% | 3.00% | 6.00% | 5.00% | 2.00% | 2.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | -2 | -3 | 10 | 3 | 23 | 24 | 7 | 6 | 2 | 5 | 3 | 0 | 1 |
| Tax | 0 | 0 | 3 | 0 | 6 | 6 | 2 | 2 | 1 | 2 | 1 | 0 | 0 |
| Net Profit | -2 | -3 | 7 | 2 | 17 | 17 | 5 | 4 | 2 | 3 | 2 | 0 | 0 |
| EPS | -7.10 | -10.72 | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 | 4.97 | 10.41 | 5.68 | 0.97 | 1.02 |
Samrat Pharmachem Cash Flow Screener - Liquidity Fundamentals
Screen SAMRATPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹9, and net cash flow was an inflow of ₹6.
Over the same period, investing activities used ₹3 and financing activities used ₹1.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 9 | -10 | 9 | -9 | 18 | 5 | -1 | 2 | 0 | -3 |
| Investing Activities | -3 | 0 | 0 | -3 | -1 | -3 | -2 | 2 | -2 | 1 |
Financing and Net Cash | ||||||||||
| Financing Activities | -1 | 1 | -11 | 10 | -2 | -2 | 2 | -4 | 2 | 1 |
| Net Cash Flow | 6 | -10 | -2 | -3 | 15 | 0 | -1 | 1 | -1 | -1 |
Samrat Pharmachem Shareholding Pattern Screener
See Samrat Pharmachem shareholding pattern with promoter, FII, and DII holdings. Check Samrat Pharmachem promoter holding and ownership changes for SAMRATPH on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 49.09%, foreign institutions 3.24%, domestic institutions 0.00% and the public 41.75%, spread across 6,311 shareholders.
The shareholder count was 6,311 in 2026-Mar, compared with 6,330 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 48.64% | 48.64% |
Institutional Investors | ||||||||
| FII Holding | 3.24% | 3.24% | 3.24% | 0.00% | 3.24% | 3.24% | 3.24% | 3.24% |
| DII Holding | 0.00% | 0.00% | 0.00% | 3.24% | 0.00% | 0.00% | 0.22% | 0.22% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 41.75% | 41.51% | 41.58% | 41.64% | 41.73% | 41.50% | 41.69% | 40.79% |
| Other Holding | 5.93% | 6.16% | 6.09% | 6.04% | 5.95% | 6.17% | 6.22% | 7.11% |
| Shareholder Count | 6,311 | 6,330 | 6,785 | 6,752 | 6,699 | 6,488 | 7,478 | 7,169 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Samrat Pharmachem. Samrat Pharmachem dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹1.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹1.00 and ₹1.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.51% |
| 2024-March | ₹1.00 | 0.32% |
| 2023-March | ₹1.00 | 0.30% |
| 2022-March | ₹1.00 | 0.28% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Samrat Pharmachem Stock Index Membership - Nifty & Sensex
See which indices include Samrat Pharmachem stock. Check SAMRATPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Samrat Pharmachem Market Events Screener - Corporate Actions
Get Samrat Pharmachem corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Samrat Pharmachem stock events that may affect SAMRATPH share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.
It is followed by Annual General Meeting dated September 23, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-14 | 2026-11-14 | Quarterly Result Announcement | NA | 0.37% |
| 2026-09-23 | 2026-09-23 | Annual General Meeting | NA | -9.22% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 7.64% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 24.45% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 1.56% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -14.06% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | -20.77% |
| 2025-09-18 | 2025-09-18 | Dividend | ₹ 1.00 /share | -18.51% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 0.67% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 24.89% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -9.48% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -16.31% |
| 2024-09-26 | 2024-09-26 | Annual General Meeting | NA | 48.09% |
| 2024-09-19 | 2024-09-19 | Dividend | ₹ 1.00 /share | 76.20% |
| 2023-09-18 | 2023-09-18 | Dividend | ₹ 1.00 /share | -18.65% |
Samrat Pharmachem Competitors Screener - Peer Stocks Comparison
Screen SAMRATPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 430,681 | 35.84 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 243,156 | 84.36 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 179,602 | 84.01 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 113,017 | 24.88 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 107,890 | 32.42 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 106,609 | 98.56 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 103,922 | 50.48 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,370 | 31.47 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,232 | 25.97 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 91,975 | 16.71 | 29,039 | 26.75% | 5,356 | 31.59 |
Samrat Pharmachem Company Announcements - News & Reports Screener
Screen SAMRATPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 28, 2026.
The next most recent announcements are dated September 28, 2026 and September 26, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-28 | Board Meeting Intimation for Board Meeting Intimation For Un-Audited Financial Results For The Quarter Ended September 30 2026 | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-26 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-09-26 | Scrutinizers Report | - |
| 2026-09-23 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-27 | Book Closure: Sunday September 20 2026 To Tuesday September 22 2026 (Both Days Inclusive) | - |
| 2026-08-27 | 34Th Annual General Meeting Of Samrat Pharmachem Limited To Be Held On Wednesday September 23 2026 | - |
| 2026-08-27 | Reg. 34 (1) Annual Report. | - |
| 2026-08-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held Today | - |
| 2026-07-17 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-07-17 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-30 | Board Meeting Intimation for Notice Of Board Meeting For Un-Audited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-06-29 | Closure of Trading Window | - |
| 2026-06-29 | Closure of Trading Window | - |
| 2026-06-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-05-30 | Audited Financial Results For The Quarter And Year Ended 31 March 2026 | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹240.40, within a 52-week range of ₹194.95 to ₹296.70. The P/E ratio is -32.61 and the P/B ratio is 1.06, with earnings per unit of ₹-10.72. Market capitalisation stands at ₹73.80 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.